17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis NCT00132015 Chronic Myelopr...
Leukemia
Lymphoma
Nonneoplastic C...
Precancerous Co...
tanespimycin
18 Years - National Institutes of Health Clinical Center (CC) View Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02992522 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center View Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02992522 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center View TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas NCT03410901 B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University View TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas NCT03410901 B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University View Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma NCT01239875 Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 Years Mayo Clinic View TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma NCT02927964 Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Folli...
Refractory Foll...
Mantle Cell Lym...
Marginal Zone L...
Ibrutinib
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University View Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma NCT01239875 Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 Years Mayo Clinic View Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas NCT04883437 Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent Non-Ho...
Lymphoplasmacyt...
Lymphoprolifera...
Mantle Cell Lym...
Marginal Zone L...
Acalabrutinib
Obinutuzumab
Quality-of-Life...
Questionnaire A...
18 Years - Emory University View Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma NCT05169658 Non-Hodgkin Lym...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent B-Cell...
Marginal Zone L...
Recurrent Extra...
Refractory Extr...
Mosunetuzumab
Obinutuzumab
Polatuzumab Ved...
18 Years - University of Washington View Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma NCT03010358 Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute View Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma NCT04450173 Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Ibrutinib
Obinutuzumab
Venetoclax
18 Years - University of California, Davis View Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02992522 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center View Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas NCT03198026 Non-Hodgkin's L...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Abor Stage ...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent Non-ho...
Stage II Spleni...
Stage III Splen...
Stage IV Spleni...
Ibrutinib
Obinutuzumab
Laboratory Biom...
18 Years - Thomas Jefferson University View Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma NCT02532257 Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
CD20 Positive
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Ibrutinib
Laboratory Biom...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center View Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma NCT01239875 Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 Years Mayo Clinic View Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma NCT04257578 B-Cell Non-Hodg...
Diffuse Large B...
High Grade B-Ce...
Primary Mediast...
Transformed Fol...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Acalabrutinib
Axicabtagene Ci...
18 Years - University of Washington View Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma NCT01000753 Adult Immunobla...
Central Nervous...
Childhood Immun...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Lymphoprolifera...
Mantle Cell Lym...
Marginal Zone L...
Non-Hodgkin Lym...
Primary Cutaneo...
Primary Cutaneo...
Small Lymphocyt...
Cytology Specim...
- 21 Years Children's Oncology Group View TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas NCT03410901 B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University View Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Mediastinal Lym...
Recurrent B-Cel...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Walde...
Refractory B-Ce...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Ibrutinib
Laboratory Biom...
Pembrolizumab
18 Years - Ohio State University Comprehensive Cancer Center View Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma NCT03010358 Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute View TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma NCT02927964 Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Folli...
Refractory Foll...
Mantle Cell Lym...
Marginal Zone L...
Ibrutinib
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University View